Hansoh Pharmaceutical Group Company Limited Stock

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:05 2024-07-18 EDT 5-day change 1st Jan Change
17.34 HKD +0.58% Intraday chart for Hansoh Pharmaceutical Group Company Limited +8.65% +10.03%

Financials

Sales 2024 * 11.83B 1.63B 12.73B 2.24B Sales 2025 * 12.33B 1.7B 13.27B 2.33B Capitalization 95.47B 13.15B 103B 18.03B
Net income 2024 * 3.79B 523M 4.08B 717M Net income 2025 * 3.8B 524M 4.09B 718M EV / Sales 2024 * 6.2 x
Net cash position 2024 * 22.11B 3.05B 23.79B 4.18B Net cash position 2025 * 24.82B 3.42B 26.7B 4.69B EV / Sales 2025 * 5.73 x
P/E ratio 2024 *
24.8 x
P/E ratio 2025 *
25 x
Employees 9,123
Yield 2024 *
0.95%
Yield 2025 *
0.97%
Free-Float 0%
More Fundamentals * Estimated data
Dynamic Chart
Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds MT
Hansoh Pharmaceutical’s 2023 Profit Up 27% MT
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 CI
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug MT
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer CI
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024 CI
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01 MT
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules MT
Hansoh Pharmaceutical Buys Back 3 Million Shares MT
Fed, China Property Outlooks Roil Asian Stock Markets MT
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug MT
China Outlook, Tech Rally Roils Asian Stock Markets MT
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets CI
More news
1 day+0.58%
1 week+8.65%
Current month+6.25%
1 month-0.80%
3 months+9.89%
6 months+37.18%
Current year+10.03%
More quotes
1 week
15.80
Extreme 15.8
17.56
1 month
15.32
Extreme 15.32
17.62
Current year
11.18
Extreme 11.18
18.76
1 year
9.41
Extreme 9.41
18.76
3 years
9.41
Extreme 9.41
33.45
5 years
9.41
Extreme 9.41
46.70
10 years
9.41
Extreme 9.41
46.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 15-12-01
Corporate Secretary 56 -
Members of the board TitleAgeSince
Director/Board Member 81 19-05-30
Director/Board Member 70 19-06-13
Director/Board Member 67 -
More insiders
Date Price Change Volume
24-07-18 17.34 +0.58% 3 215 680
24-07-17 17.24 +4.48% 3,303,796
24-07-16 16.5 +0.24% 4,378,234
24-07-15 16.46 -2.02% 2,154,577
24-07-12 16.8 +4.87% 3,754,442

Delayed Quote Hong Kong S.E., July 18, 2024 at 04:08 am

More quotes
Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows: - sales of pharmaceutical products (99.1%); - sales of research and development services (0.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
16.12 CNY
Average target price
18.16 CNY
Spread / Average Target
+12.65%
Consensus

Quarterly revenue - Rate of surprise